Product Description
- The Finecare CEA Rapid Quantitative Test is a fluorescence immunoassay used along with Finecare FIA System for quantitative determination of carcino-embryonic antigen in human whole blood, serum or plasma. The test is used as an aid in the evaluation of therapeutic efficiency, prognosis and recurrence monitoring for carcinoma.
- STORAGE AND STABILITY1. Store the test kit at 430 up to the expiration date printed on package.
2. If removed from refrigerator, allow the test kit for 30 minutes to return to room temperature before testing.
3. Do not remove the Test Cartridge from the pouch until use. The Test Cartridge should be used within 1 hour once opened.
Technical Details 
Fast and Accurate CEA QuantificationDesigned for in vitro diagnostics, the Finecare CEA Rapid Quantitative Test provides swift and dependable CEA measurements using an advanced sandwich immunodetection principle. Within just 15 minutes, users receive high-sensitivity results displayed directly on the Finecare Meter. This quick turnaround enhances workflow efficiency in clinical and point-of-care settings, facilitating timely decision-making.
Effortless Operation with Minimal SampleEach test requires only 75 L of serum, plasma, or whole blood, ensuring ease of collection and minimizing patient discomfort. The automatic process, driven by the Finecare FIA Meter, eliminates manual interpretation and streamlines the assay for all levels of laboratory professionals. Lightweight and portable, the system is perfect for diverse healthcare environments.
Safe Storage and ComplianceTests are individually packaged for quality assurance and convenience. With an 18-month shelf life and CE/IVD certification, each cartridge should be stored at 2~30C, away from sunlight and moisture to maintain integrity. Used cartridges must be disposed of via standard biohazard waste protocols, ensuring safety and regulatory compliance.
FAQs of Finecare CEA Rapid Quantitative Test:
Q: How does the Finecare CEA Rapid Quantitative Test work?
A: The test employs a sandwich immunodetection principle combined with fluorescence immunoassay (FIA) technology. Once a blood, serum, or plasma sample is added to the cartridge, the assay automatically measures CEA concentrations using the Finecare FIA Meter, delivering quantitative results within 15 minutes.
Q: What types of samples are compatible with this test?
A: This test is compatible with human serum, plasma, or whole blood samples. You only need 75 L to run an assay, making it convenient for both venous and finger-prick collections.
Q: When should I use the Finecare CEA Rapid Quantitative Test?
A: This test is intended for use whenever there is a clinical need to quantitatively detect Carcinoembryonic Antigen in human samples, such as during cancer diagnostics or monitoring. It is suitable for use in hospitals, clinical laboratories, and point-of-care settings.
Q: Where can the test be used and who can operate it?
A: The Finecare CEA Rapid Quantitative Test is designed for use in clinical laboratories, hospitals, or at the point of care. It should be performed by healthcare, laboratory, or point-of-care professionals trained to operate immunoassay equipment.
Q: What is the process for running a test and obtaining results?
A: Simply collect the appropriate sample, dispense 75 L into a test cartridge, and insert it into the Finecare FIA Meter. The device will automatically process the assay and display CEA results on-screen within 15 minutes.
Q: How should I store the test cartridges and for how long?
A: Store cartridges at a temperature between 2~30C, away from direct sunlight and moisture, maintaining relative humidity at or below 80% (non-condensing). Each cartridge has an 18-month shelf liferefer to the individual pouch for expiry details.
Q: What are the key benefits of using this test?
A: The Finecare CEA Rapid Quantitative Test offers high sensitivity and specificity, fast results, minimal sample requirement, easy operation, and compatibility with portable FIA Meters. It is single-use, ensures silent operation, and aids prompt clinical decision-making.